(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of 69.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.59%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.82%.
Invivyd's revenue in 2026 is $53,426,000.On average, 6 Wall Street analysts forecast IVVD's revenue for 2026 to be $37,392,934,541, with the lowest IVVD revenue forecast at $20,189,132,629, and the highest IVVD revenue forecast at $78,456,774,612. On average, 6 Wall Street analysts forecast IVVD's revenue for 2027 to be $45,901,861,831, with the lowest IVVD revenue forecast at $14,677,970,224, and the highest IVVD revenue forecast at $105,656,517,279.
In 2028, IVVD is forecast to generate $77,015,541,494 in revenue, with the lowest revenue forecast at $36,112,780,419 and the highest revenue forecast at $133,390,363,983.